All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis
et al., Cardiology Plus, doi:10.1097/CP9.0000000000000049, Apr 2023
Azvudine for COVID-19
47th treatment shown to reduce risk in
January 2023, now with p = 0.000000017 from 39 studies.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
PSM retrospective 332 hospitalized moderate to critically ill COVID-19 patients with myocardial injury in China, showing improved 14 day mortality but no difference in overall in-hospital mortality with azvudine treatment.
Standard of Care (SOC) for COVID-19 in the study country,
China, is average with moderate efficacy for approved treatments3.
This may explain in part the very high mortality seen in this study.
|
risk of death, 6.5% lower, RR 0.94, p = 0.88, treatment 29 of 99 (29.3%), control 31 of 99 (31.3%), NNT 49, in-hospital mortality, propensity score matching.
|
|
risk of death, 63.0% lower, HR 0.37, p = 0.007, treatment 99, control 99, propensity score matching, day 14.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
1.
Xiong et al., Real-world data of Azvudine-induced hepatotoxicity among hospitalized COVID-19 patients in China: a retrospective case-control study, Frontiers in Pharmacology, doi:10.3389/fphar.2025.1558054.
Chen et al., 30 Apr 2023, retrospective, China, peer-reviewed, 9 authors.
Figure S1. Love plot displaying standardized differences for the baseline characteristics by the use of azvudine in patients with myocardial injuries, before and after propensity score matching. SBP: systolic blood pressure; DBP: diastolic blood pressure; RR: respiratory rate; HR: heart rate
DOI record:
{
"DOI": "10.1097/cp9.0000000000000049",
"ISSN": [
"2470-7511"
],
"URL": "http://dx.doi.org/10.1097/CP9.0000000000000049",
"abstract": "<jats:sec>\n <jats:title>Background and purpose:</jats:title>\n <jats:p>Omicron is currently the dominant strain of severe acute respiratory syndrome coronavirus 2, but little is known about the characteristics and management of omicron related myocardial injury, particularly the potential benefit of the antiviral agent azvudine.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Methods:</jats:title>\n <jats:p>Patients with confirmed and suspected coronavirus disease 2019 (COVID-19) admitted to Wuhan Union Hospital from December 7, 2022, to December 30, 2022, were included in this study. Cox regression was conducted to identify risk factors for all-cause mortality. A propensity score-matched analysis was performed at a 1:1 ratio with a caliper of 0.1 pooled standard deviations of relevant confounders.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Results:</jats:title>\n <jats:p>The final analysis included a total of 332 patients (167 confirmed cases and 165 suspected cases), 42.77% (142/332) of the patients were 80 years of age or older and 68.67% (228/332) of them were men, 158 patients were treated with azvudine. In the matched cohort, the total mortality was 30.30% (60/198), 40 (20.20%, 40/198) patients received noninvasive ventilation and 22 (11.11%, 22/198) received invasive ventilation, 34 (17.17%, 34/198) patients were admitted to intensive care unit (ICU). The rate of shock, multiple organ damages and arrhythmia were 11.62% (23/198), 20.20% (40/198), and 12.12% (24/198), respectively. There was no significant difference on these clinical outcomes in patients treated with azvudine or not. Azvudine reduced early mortality (within 14 days from admission) (hazard ratio: 0.37, 95% confidence interval: 0.18–0.77) even after adjusting for other treatments including glucocorticoids, immunoglobin and anticoagulant therapy, but not the final in-hospital mortality of patients.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Conclusions:</jats:title>\n <jats:p>Patients with COVID-19-related myocardial injury had a high mortality of about 30.30% (60/198). Azvudine improved the early survival of the patients but not final mortality.</jats:p>\n </jats:sec>",
"author": [
{
"affiliation": [
{
"name": "Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
},
{
"name": "Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Chen",
"given": "Ru",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
},
{
"name": "Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Guo",
"given": "Yi",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
},
{
"name": "Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Deng",
"given": "Shan",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Wang",
"given": "Jian",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Liyuan Cardiovascular Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Gao",
"given": "Meng",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Liyuan Cardiovascular Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Han",
"given": "Hongli",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
},
{
"name": "Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Wang",
"given": "Lin",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Jiang",
"given": "Hongwei",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
},
{
"name": "Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China."
},
{
"name": "Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan 430022, China."
},
{
"name": "Hubei clinical research center of metabolic and cardiovascular disease, Huazhong University of Science and Technology, Wuhan 430022, China."
}
],
"family": "Huang",
"given": "Kai",
"sequence": "additional"
}
],
"container-title": "Cardiology Plus",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2023,
6,
8
]
],
"date-time": "2023-06-08T10:00:35Z",
"timestamp": 1686218435000
},
"deposited": {
"date-parts": [
[
2023,
7,
20
]
],
"date-time": "2023-07-20T13:27:44Z",
"timestamp": 1689859664000
},
"indexed": {
"date-parts": [
[
2024,
2,
23
]
],
"date-time": "2024-02-23T19:48:28Z",
"timestamp": 1708717708740
},
"is-referenced-by-count": 2,
"issue": "2",
"issued": {
"date-parts": [
[
2023,
4
]
]
},
"journal-issue": {
"issue": "2",
"published-print": {
"date-parts": [
[
2023
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by-sa/4.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2023,
4,
1
]
],
"date-time": "2023-04-01T00:00:00Z",
"timestamp": 1680307200000
}
}
],
"link": [
{
"URL": "https://journals.lww.com/10.1097/CP9.0000000000000049",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "276",
"original-title": [],
"page": "103-110",
"prefix": "10.1097",
"published": {
"date-parts": [
[
2023,
4
]
]
},
"published-online": {
"date-parts": [
[
2023,
5,
31
]
]
},
"published-print": {
"date-parts": [
[
2023,
4
]
]
},
"publisher": "Ovid Technologies (Wolters Kluwer Health)",
"reference": [
{
"DOI": "10.1002/jmv.27376",
"article-title": "The global epidemic of SARS-CoV-2 variants and their mutational immune escape.",
"author": "Tian",
"doi-asserted-by": "crossref",
"first-page": "847",
"journal-title": "J Med Virol",
"key": "R1-20230720",
"volume": "94",
"year": "2022"
},
{
"DOI": "10.1002/jmv.27524",
"article-title": "Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.",
"author": "Saxena",
"doi-asserted-by": "crossref",
"first-page": "1738",
"journal-title": "J Med Virol",
"key": "R2-20230720",
"volume": "94",
"year": "2022"
},
{
"DOI": "10.1016/j.micres.2022.127204",
"article-title": "Omicron variant: current insights and future directions.",
"author": "Rana",
"doi-asserted-by": "crossref",
"first-page": "127204",
"journal-title": "Microbiol Res",
"key": "R3-20230720",
"volume": "265",
"year": "2022"
},
{
"DOI": "10.1002/jmv.27588",
"article-title": "Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines.",
"author": "Araf",
"doi-asserted-by": "crossref",
"first-page": "1825",
"journal-title": "J Med Virol",
"key": "R4-20230720",
"volume": "94",
"year": "2022"
},
{
"DOI": "10.1016/S0140-6736(22)00327-0",
"article-title": "Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.",
"author": "Menni",
"doi-asserted-by": "crossref",
"first-page": "1618",
"journal-title": "Lancet",
"key": "R5-20230720",
"volume": "399",
"year": "2022"
},
{
"DOI": "10.1001/jamacardio.2020.1017",
"article-title": "Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19).",
"author": "Guo",
"doi-asserted-by": "crossref",
"first-page": "811",
"journal-title": "JAMA Cardiol",
"key": "R6-20230720",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1016/j.ajem.2020.04.048",
"article-title": "Cardiovascular complications in COVID-19.",
"author": "Long",
"doi-asserted-by": "crossref",
"first-page": "1504",
"journal-title": "Am J Emerg Med",
"key": "R7-20230720",
"volume": "38",
"year": "2020"
},
{
"DOI": "10.1016/S0140-6736(20)30566-3",
"article-title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.",
"author": "Zhou",
"doi-asserted-by": "crossref",
"first-page": "1054",
"journal-title": "Lancet",
"key": "R8-20230720",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.1001/jamacardio.2020.3557",
"article-title": "Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19).",
"author": "Puntmann",
"doi-asserted-by": "crossref",
"first-page": "1265",
"journal-title": "JAMA Cardiol",
"key": "R9-20230720",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2119658",
"article-title": "Population immunity and covid-19 severity with Omicron variant in South Africa.",
"author": "Madhi",
"doi-asserted-by": "crossref",
"first-page": "1314",
"journal-title": "N Engl J Med",
"key": "R10-20230720",
"volume": "386",
"year": "2022"
},
{
"DOI": "10.15585/mmwr.mm7106e2",
"article-title": "Clinical characteristics and outcomes among adults Hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance - one hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.",
"author": "Modes",
"doi-asserted-by": "crossref",
"first-page": "217",
"journal-title": "MMWR Morb Mortal Wkly Rep",
"key": "R11-20230720",
"volume": "71",
"year": "2022"
},
{
"DOI": "10.1016/S1473-3099(22)00141-4",
"article-title": "Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.",
"author": "Sheikh",
"doi-asserted-by": "crossref",
"first-page": "959",
"journal-title": "Lancet Infect Dis",
"key": "R12-20230720",
"volume": "22",
"year": "2022"
},
{
"DOI": "10.1093/ehjcr/ytac407",
"article-title": "First report of myocarditis in two patients with COVID-19 Omicron variant: case report.",
"author": "Fishman",
"doi-asserted-by": "crossref",
"first-page": "ytac407",
"journal-title": "Eur Heart J Case Rep",
"key": "R13-20230720",
"volume": "6",
"year": "2022"
},
{
"DOI": "10.1038/d41586-022-00112-8",
"article-title": "Why scientists are racing to develop more COVID antivirals.",
"author": "Kozlov",
"doi-asserted-by": "crossref",
"first-page": "496",
"journal-title": "Nature",
"key": "R14-20230720",
"volume": "601",
"year": "2022"
},
{
"DOI": "10.1093/cid/ciac180",
"article-title": "Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs.",
"author": "Saravolatz",
"doi-asserted-by": "crossref",
"first-page": "165",
"journal-title": "Clin Infect Dis",
"key": "R15-20230720",
"volume": "76",
"year": "2023"
},
{
"DOI": "10.1038/s41392-020-00351-z",
"article-title": "Azvudine (FNC): a promising clinical candidate for COVID-19 treatment.",
"author": "Yu",
"doi-asserted-by": "crossref",
"first-page": "236",
"journal-title": "Signal Transduct Target Ther",
"key": "R16-20230720",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1002/advs.202001435",
"article-title": "A randomized, open-label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID-19, a pilot study.",
"author": "Ren",
"doi-asserted-by": "crossref",
"first-page": "e2001435",
"journal-title": "Adv Sci (Weinh)",
"key": "R17-20230720",
"volume": "7",
"year": "2020"
},
{
"article-title": "Guidelines for the diagnosis and treatment of coronavirus disease 2019 (Ninth Trial Version).",
"first-page": "161",
"journal-title": "Chin J Viral Dis",
"key": "R18-20230720",
"volume": "12",
"year": "2022"
},
{
"DOI": "10.1016/S0140-6736(20)30183-5",
"article-title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",
"author": "Huang",
"doi-asserted-by": "crossref",
"first-page": "497",
"journal-title": "Lancet",
"key": "R19-20230720",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.1214/09-STS313",
"article-title": "Matching methods for causal inference: a review and a look forward.",
"author": "Stuart",
"doi-asserted-by": "crossref",
"first-page": "1",
"journal-title": "Stat Sci",
"key": "R20-20230720",
"volume": "25",
"year": "2010"
},
{
"DOI": "10.1093/cvr/cvaa078",
"article-title": "The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.",
"author": "Chen",
"doi-asserted-by": "crossref",
"first-page": "1097",
"journal-title": "Cardiovasc Res",
"key": "R21-20230720",
"volume": "116",
"year": "2020"
},
{
"DOI": "10.1016/j.jacc.2020.08.069",
"article-title": "Characterization of myocardial injury in patients with COVID-19.",
"author": "Giustino",
"doi-asserted-by": "crossref",
"first-page": "2043",
"journal-title": "J Am Coll Cardiol",
"key": "R22-20230720",
"volume": "76",
"year": "2020"
},
{
"DOI": "10.1016/j.cell.2020.02.058",
"article-title": "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.",
"author": "Walls",
"doi-asserted-by": "crossref",
"first-page": "281",
"journal-title": "Cell",
"key": "R23-20230720",
"volume": "181",
"year": "2020"
},
{
"DOI": "10.1007/s11357-020-00198-w",
"article-title": "COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches.",
"author": "Moccia",
"doi-asserted-by": "crossref",
"first-page": "1021",
"journal-title": "Geroscience",
"key": "R24-20230720",
"volume": "42",
"year": "2020"
},
{
"DOI": "10.1038/s41577-020-0311-8",
"article-title": "The trinity of COVID-19: immunity, inflammation and intervention.",
"author": "Tay",
"doi-asserted-by": "crossref",
"first-page": "363",
"journal-title": "Nat Rev Immunol",
"key": "R25-20230720",
"volume": "20",
"year": "2020"
},
{
"DOI": "10.1007/s11739-009-0297-5",
"article-title": "The microcirculation as a diagnostic and therapeutic target in sepsis.",
"author": "Nencioni",
"doi-asserted-by": "crossref",
"first-page": "413",
"journal-title": "Intern Emerg Med",
"key": "R26-20230720",
"volume": "4",
"year": "2009"
},
{
"DOI": "10.1007/s10741-021-10087-9",
"article-title": "COVID-19 and myocarditis: a systematic review and overview of current challenges.",
"author": "Castiello",
"doi-asserted-by": "crossref",
"first-page": "251",
"journal-title": "Heart Fail Rev",
"key": "R27-20230720",
"volume": "27",
"year": "2022"
},
{
"DOI": "10.1016/j.hrthm.2020.05.001",
"article-title": "Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management.",
"author": "Siripanthong",
"doi-asserted-by": "crossref",
"first-page": "1463",
"journal-title": "Heart Rhythm",
"key": "R28-20230720",
"volume": "17",
"year": "2020"
},
{
"article-title": "Myocardial injury in patients with COVID-19 pneumonia.",
"author": "Wei",
"first-page": "E006",
"journal-title": "Zhonghua Xin Xue Guan Bing Za Zhi",
"key": "R29-20230720",
"volume": "48",
"year": "2020"
},
{
"article-title": "The first Chinese oral anti-COVID-19 drug Azvudine launched.",
"author": "Yu",
"first-page": "100321",
"journal-title": "Innovation (Camb)",
"key": "R30-20230720",
"volume": "3",
"year": "2022"
}
],
"reference-count": 30,
"references-count": 30,
"relation": {},
"resource": {
"primary": {
"URL": "https://journals.lww.com/10.1097/CP9.0000000000000049"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Cardiology and Cardiovascular Medicine"
],
"subtitle": [],
"title": "All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis",
"type": "journal-article",
"volume": "8"
}
Late treatment
is less effective
is less effective
